ARVN Overview
Upcoming Projects (ARVN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ARVN)
-
Discussing highlights from ESMO in breast cancer: Pfizer's CDK4-selective inhibitor PF-07220060, Arvinas/Pfizer Vepdegestrant/palbociclib combo & Olema's palazestrant/ribociclib combo
Tickers: PFE, ARVN, OLMA
Executed On: Jun 10, 2024 at 09:00 AM EDT -
Reviewing Arvinas' ARV-471 as a monotherapy protein degrader in ER+/HER2- Advanced Breast Cancer
Ticker: ARVN
Executed On: Apr 10, 2023 at 02:30 PM EDT -
A Second View: Examining the potential of Arvinas' Novel PROTAC Degrader Bavdegalutamide (ARV-110) in prostate cancer
Ticker: ARVN
Executed On: Feb 28, 2023 at 02:45 PM EST -
Examining the potential of Arvinas' Novel PROTAC Degrader Bavdegalutamide (ARV-110) in prostate cancer
Ticker: ARVN
Executed On: Feb 24, 2023 at 08:30 AM EST
Upcoming & Overdue Catalysts (ARVN)
-
ARV-471 Phase 3 trial
Tickers: ARVN, PFE, OLMA
Future Window: Oct 01, 2023 - Dec 31, 2024
Occurred Catalysts (ARVN)
-
Arvinas (ARVN) Releases Interim Clinical Data of PROTAC Protein Degraders ARV-471 and ARV-110
Ticker: ARVN
Occurred on: Dec 14, 2020
Strategic Initiatives (ARVN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
